MacroGenics Signs $586 Million Licensing Deal With Synaffix for Antibody-Drug Conjugate Technology

Edward Kim  |

Image source: MacroGenics

Rockville, Maryland-based MacroGenics  MGNX announced a licensing deal Thursday for multiple antibody-drug conjugate (ADC) technologies from

Synaffix, a Netherlands-based biotech firm developing ADCs, bispecific antibodies and other targeted therapeutics under an out-licensing business model.

MacroGenics, which went public on The Nasdaq Stock Market in 2013, is a clinical-stage company focused on developing monoclonal antibody-based therapeutics for the treatment of cancer. The company will use Synaffix technologies to develop next generation ADCs for three clinical programs.

Deal terms

introtext

MacroGenics will gain access to these Synaffix technologies:

  • GlycoConnect antibody conjugation technology
  • HydraSpace polar spacer technology
  • Select toxSYN linker-payloads (SYNtecan E, SYNeamicin D and SYNeamicin G), each designed to enable ADCs with best-in-class efficacy and tolerability

Synaffix will be eligible to receive up to $586 million in payments spanning upfront and milestone payments, in addition to royalties on commercial sales.

The first program will commence immediately with the option to expand the deal to a further two programs by March 2023.

MacroGenics will be responsible for research, development, manufacturing and commercialization, while Synaffix will provide research and be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

Investment thesis

Click to enlarge

Image source: BigCharts

MacroGenics stock has collapsed nearly 70% since hitting $36.48 last spring after it received its first FDA approval in December 2020 of Margenza (margetuximab-cmkb) for the treatment of adults with metastatic HER2-positive breast cancer who have received at least two prior anti-HER2 regimens, at least one of which was for metastatic disease.

  • Even before the Margenza approval, MacroGenics had a track record of generating revenue through collaborative and government agreements to the tune of $690 million since going public.
  • The company had $299 million in cash and marketable securities as of Sept. 30, 2021, which gives it a runway through 2023, assuming continued collaborative and government agreements. At the current market cap of $674 million, the market is valuing the entirety of MacroGenics clinical program at under $400 million.
  • MacroGenics has multiple clinical milestones anticipated for 2022.
  • At $11 per share, with this new licensing deal in place, and a demonstrated ability to get a drug through the FDA gauntlet, we think investors with a high risk appetite can effectively view MacroGenics stock as a low-priced call option on a diverse portfolio of potentially breakthrough cancer therapies.

Click to enlarge

Image source: MacroGenics

_____

Source: Equities News

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

Trending Articles

Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast
Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement
Target Hits 52-Week Low After Missing Badly on First Quarter Earnings
DLocal Posts Record Q1, Fifth Consecutive 100%+ Revenue Growth Quarter
Another Crypto Winter Wipes Out Billions in Market Value
Inflation + Recession = Recipe for Volatility

Market Movers

Sponsored Financial Content